Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,103Revenue $M6.5Net Margin (%)-3,700.1Altman Z-Score145
Enterprise Value $M7,393EPS $-5.9Operating Margin %-3,683.0Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.7Pre-tax Margin (%)-3,686.7Higher ROA y-yN
Price/Book10.810-y EBITDA Growth Rate %--Quick Ratio25.9Cash flow > EarningsY
Price/Sales1,2125-y EBITDA Growth Rate %--Current Ratio25.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-35.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-37.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M37.2ROIC % (ttm)-803.7Gross Margin Increase y-yN

Gurus Latest Trades with GEVA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GEVAGeorge Soros 2013-12-31 Sold Out -0.01%$45.51 - $69.69
($59.17)
$ 218.11269%Sold Out0
GEVAGeorge Soros 2013-09-30 Buy 0.01%$43.26 - $62.55
($49.11)
$ 218.11344%New holding17,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GEVA is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GEVA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Williams GlenSVP, Technical Operations 2015-05-06Sell1,666$205.626.07 view
Quinn AnthonyEVP, CMO & Head of R&D 2015-04-27Sell10,000$11098.28 view
Quinn AnthonyEVP, CMO & Head of R&D 2015-04-21Sell10,000$108101.95 view
Quinn AnthonyEVP, CMO & Head of R&D 2015-04-15Sell10,000$105107.72 view
Williams GlenSVP, Technical Operations 2015-04-08Sell42,632$96.08127.01 view
Quinn AnthonyEVP, CMO & Head of R&D 2015-04-06Sell29,503$93.76132.63 view
Heberlig ChrisSVP, Finance and Business Ops. 2015-03-11Sell7,500$103.17111.41 view
BOESS CARSTENSVP, CFO 2015-02-17Sell42,297$100.11117.87 view
BAKER FELIXDirector, 10% Owner 2015-01-07Buy1,000,000$94.19131.56 view
BAKER JULIANDirector, 10% Owner 2015-01-07Buy1,000,000$94.19131.56 view

Press Releases about GEVA :

Quarterly/Annual Reports about GEVA:

News about GEVA:

Articles On GuruFocus.com
Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
Wednesday Pre-Market Insights: GEVA, BRDR, MGI, NDLS, ZU May 06 2015 

More From Other Websites
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... May 22 2015
Pall-Danaher Transaction: What You Should Know about Danaher May 21 2015
Pall-Danaher Transaction: An Overview of Pall May 21 2015
Intercept's NASH Trial Design Irks Investors May 19 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synageva BioPharma Corp. of... May 18 2015
SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of... May 18 2015
15 biotech stocks to put on your watch list now May 15 2015
Should You Set Up the Synageva BioPharma–Alexion Spread? May 14 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva... May 13 2015
Alexion Pharmaceuticals: A Focus on Treating Rare Disorders May 13 2015
Synageva BioPharma: A Pipeline of Therapeutic Programs May 13 2015
Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog May 13 2015
The Synageva–Alexion Merger: Stock and Cash Considerations May 12 2015
Alexion Pharmaceuticals Pays up to Get Synageva BioPharma May 12 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synageva BioPharma Corp. of... May 12 2015
Oppenheimer Downgrades Dyax May 11 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva... May 11 2015
These biotech names are ripe for mergers: Analysts May 10 2015
Charting the Market May 08 2015
SYNAGEVA BIOPHARMA CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout May 08 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK